Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ORTHOPEDIATRICS CORP.

(KIDS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/01/2021 12/02/2021 12/03/2021 12/06/2021 12/07/2021 Date
55.37(c) 58.3(c) 57.02(c) 57.35(c) 61.41 Last
112 976 81 806 90 152 67 004 123 109 Volume
-0.61% +5.29% -2.20% +0.58% +7.08% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 98,0 M - -
Net income 2021 -23,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -48,2x
Yield 2021 -
Sales 2022 119 M - -
Net income 2022 -15,3 M - -
Net Debt 2022 - - -
P/E ratio 2022 -73,9x
Yield 2022 -
Capitalization 1 129 M 1 129 M -
Capi. / Sales 2021 11,5x
Capi. / Sales 2022 9,45x
Nbr of Employees 116
Free-Float 69,9%
More Financials
Company
OrthoPediatrics Corp. is a medical device company, which is designing, developing and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers. The Company operates through the OrthoPediatrics Segment, which designs, develops and markets anatomically appropriate implants and devices for children with orthopedic problems. The... 
More about the company
Ratings of OrthoPediatrics Corp.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D
More Ratings
All news about ORTHOPEDIATRICS CORP.
11/22OrthoPediatrics to Participate in the 33rd Annual Piper Sandler Virtual Healthcare Conf..
AQ
11/08ORTHOPEDIATRICS CORP : Regulation FD Disclosure, Financial Statements and Exhibits (form 8..
AQ
11/04ORTHOPEDIATRICS CORP : Entry into a Material Definitive Agreement, Change in Directors or ..
AQ
11/04ORTHOPEDIATRICS CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
AQ
11/03OrthoPediatrics Corp. Reports Third Quarter 2021 Financial Results - Form 8-K
PU
11/03OrthoPediatrics Corp. Reports Earnings Results for the Third Quarter and Nine Months En..
CI
11/03Orthopediatrics Corp. Provides Earnings Guidance for the Year Ending December 31, 2021
CI
11/03ORTHOPEDIATRICS : Q3 Earnings Snapshot
AQ
11/03Earnings Flash (KIDS) ORTHOPEDIATRICS Reports Q3 Loss $-0.15
MT
11/03Earnings Flash (KIDS) ORTHOPEDIATRICS Reports Q3 Revenue $25.1M
MT
11/03OrthoPediatrics Corp. Reports Third Quarter 2021 Financial Results
AQ
10/26OrthoPediatrics to Participate in the Stifel 2021 Virtual Healthcare Conference
GL
10/18ORTHOPEDIATRICS : Recognized in COVID Stops Here Campaign
AQ
10/13ORTHOPEDIATRICS : Expects Q3 Revenue to Rise 13% Sequentially; Reaffirms 2021 Guidance
MT
10/13ORTHOPEDIATRICS : Announces Preliminary Unaudited Revenue for the Third Quarter 2021 and R..
AQ
More news
News in other languages on ORTHOPEDIATRICS CORP.
11/03Orthopediatrics Corp. fournit des prévisions de résultats pour l'année se terminant le ..
11/03Earnings Flash (KIDS) ORTHOPEDIATRICS annonce un chiffre d'affaires de 25,1 millions de..
10/13OrthoPediatrics prévoit une hausse séquentielle de 13 % de ses revenus au troisième tri..
10/13OrthoPediatrics Corp. fournit des prévisions de revenus préliminaires pour le troisième..
09/10OrthoPediatrics et SeaSpine Unit concluent un accord de distribution pour le système de..
More news
Analyst Recommendations on ORTHOPEDIATRICS CORP.
More recommendations
Chart ORTHOPEDIATRICS CORP.
Duration : Period :
OrthoPediatrics Corp. Technical Analysis Chart | KIDS | US68752L1008 | MarketScreener
Technical analysis trends ORTHOPEDIATRICS CORP.
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 57,35 $
Average target price 78,83 $
Spread / Average Target 37,5%
EPS Revisions
Managers and Directors
David R. Bailey President, Chief Executive Officer & Director
Fred L. Hite Director, Chief Operating & Financial Officer
Mark C. Throdahl Executive Chairman
Peter F. Armstrong Chief Medical Officer
Joel Batts Senior Vice President-Science & Technology
Sector and Competitors